FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981637932> ?p ?o ?g. }

• W2981637932 endingPage "401" @default.
• W2981637932 startingPage "388" @default.
• W2981637932 abstract "Background and Purpose The 5‐lipoxygenase product 5‐oxo‐6E,8Z,11Z,14Z‐eicosatetraenoic acid (5‐oxo‐ETE), acting through the OXE receptor, is a potent eosinophil chemoattractant that may be an important proinflammatory mediator in eosinophilic diseases such as asthma. We previously identified a series of indole‐based OXE receptor antagonists that rapidly appear in the blood following oral administration but have limited lifetimes. The objective of this study was to increase the potency and plasma half‐lives of these compounds and thereby identify the optimal candidate for future preclinical studies in monkeys, as rodents do not have an OXE receptor orthologue. Experimental Approach We synthesized a series of substituted phenylalkyl indoles and compared their antagonist potencies, pharmacokinetics, and metabolism to those of our earlier compounds. The potencies of some of their metabolites were also investigated. Key Results Among the compounds tested, the S‐ enantiomer of the m‐chlorophenyl compound ( S‐ Y048 ) was the most potent, with an pIC 50 of about 10.8 for inhibition of 5‐oxo‐ETE‐induced calcium mobilization in human neutrophils. When administered orally to cynomolgus monkeys, S‐ Y048 rapidly appeared in the blood and had a half‐life in plasma of over 7 hr, considerably longer than any of the other OXE analogues tested. A major hydroxylated metabolite, with a potency close to that of its precursor, was identified in plasma. Conclusion and Implications Because of its highly potent antagonist activity and its long lifetime in vivo, S‐ Y048 may be a useful anti‐inflammatory agent for the treatment of eosinophilic diseases such as asthma, allergic rhinitis, and atopic dermatitis." @default.
• W2981637932 created "2019-11-01" @default.
• W2981637932 creator A5008842372 @default.
• W2981637932 creator A5022704926 @default.
• W2981637932 creator A5028764377 @default.
• W2981637932 creator A5047553096 @default.
• W2981637932 creator A5052440022 @default.
• W2981637932 creator A5060846796 @default.
• W2981637932 creator A5064142865 @default.
• W2981637932 creator A5070022221 @default.
• W2981637932 creator A5070812231 @default.
• W2981637932 creator A5083960288 @default.
• W2981637932 date "2020-01-01" @default.
• W2981637932 modified "2023-10-13" @default.
• W2981637932 title "Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys" @default.
• W2981637932 cites W1522245921 @default.
• W2981637932 cites W1564740964 @default.
• W2981637932 cites W1593555249 @default.
• W2981637932 cites W1654089893 @default.
• W2981637932 cites W1867566681 @default.
• W2981637932 cites W1946388854 @default.
• W2981637932 cites W1967781579 @default.
• W2981637932 cites W2017493172 @default.
• W2981637932 cites W2024876767 @default.
• W2981637932 cites W2034133667 @default.
• W2981637932 cites W2041133538 @default.
• W2981637932 cites W2052104184 @default.
• W2981637932 cites W2059009993 @default.
• W2981637932 cites W2061676392 @default.
• W2981637932 cites W2075026744 @default.
• W2981637932 cites W2083856546 @default.
• W2981637932 cites W2085355988 @default.
• W2981637932 cites W2125166909 @default.
• W2981637932 cites W2150091654 @default.
• W2981637932 cites W2171057898 @default.
• W2981637932 cites W2173174985 @default.
• W2981637932 cites W2325733949 @default.
• W2981637932 cites W2339103298 @default.
• W2981637932 cites W2536022678 @default.
• W2981637932 cites W2610348898 @default.
• W2981637932 cites W2626246102 @default.
• W2981637932 cites W2739837921 @default.
• W2981637932 cites W2765684626 @default.
• W2981637932 cites W2766306821 @default.
• W2981637932 cites W2771328536 @default.
• W2981637932 cites W2799420115 @default.
• W2981637932 cites W2808275039 @default.
• W2981637932 cites W2810811103 @default.
• W2981637932 cites W2810953135 @default.
• W2981637932 cites W2883434132 @default.
• W2981637932 cites W2952118622 @default.
• W2981637932 cites W401798601 @default.
• W2981637932 doi "https://doi.org/10.1111/bph.14874" @default.
• W2981637932 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6989946" @default.
• W2981637932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31655025" @default.
• W2981637932 hasPublicationYear "2020" @default.
• W2981637932 type Work @default.
• W2981637932 sameAs 2981637932 @default.
• W2981637932 citedByCount "9" @default.
• W2981637932 countsByYear W29816379322020 @default.
• W2981637932 countsByYear W29816379322021 @default.
• W2981637932 countsByYear W29816379322022 @default.
• W2981637932 countsByYear W29816379322023 @default.
• W2981637932 crossrefType "journal-article" @default.
• W2981637932 hasAuthorship W2981637932A5008842372 @default.
• W2981637932 hasAuthorship W2981637932A5022704926 @default.
• W2981637932 hasAuthorship W2981637932A5028764377 @default.
• W2981637932 hasAuthorship W2981637932A5047553096 @default.
• W2981637932 hasAuthorship W2981637932A5052440022 @default.
• W2981637932 hasAuthorship W2981637932A5060846796 @default.
• W2981637932 hasAuthorship W2981637932A5064142865 @default.
• W2981637932 hasAuthorship W2981637932A5070022221 @default.
• W2981637932 hasAuthorship W2981637932A5070812231 @default.
• W2981637932 hasAuthorship W2981637932A5083960288 @default.
• W2981637932 hasBestOaLocation W29816379321 @default.
• W2981637932 hasConcept C112705442 @default.
• W2981637932 hasConcept C149151106 @default.
• W2981637932 hasConcept C150903083 @default.
• W2981637932 hasConcept C170493617 @default.
• W2981637932 hasConcept C185592680 @default.
• W2981637932 hasConcept C202751555 @default.
• W2981637932 hasConcept C203014093 @default.
• W2981637932 hasConcept C207001950 @default.
• W2981637932 hasConcept C2776042228 @default.
• W2981637932 hasConcept C2776885963 @default.
• W2981637932 hasConcept C2777037409 @default.
• W2981637932 hasConcept C2777477808 @default.
• W2981637932 hasConcept C55493867 @default.
• W2981637932 hasConcept C57992300 @default.
• W2981637932 hasConcept C86803240 @default.
• W2981637932 hasConcept C98274493 @default.
• W2981637932 hasConceptScore W2981637932C112705442 @default.
• W2981637932 hasConceptScore W2981637932C149151106 @default.
• W2981637932 hasConceptScore W2981637932C150903083 @default.
• W2981637932 hasConceptScore W2981637932C170493617 @default.
• W2981637932 hasConceptScore W2981637932C185592680 @default.
• W2981637932 hasConceptScore W2981637932C202751555 @default.
• W2981637932 hasConceptScore W2981637932C203014093 @default.

• next